<DOC>
	<DOC>NCT01936805</DOC>
	<brief_summary>The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel revascularization (TVR), or stroke.</brief_summary>
	<brief_title>ROsuvastatin LOading and Clinical Outcomes Trial</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>statinnaive patients stable ischemic heart disease de novo lesions appropriate for PCI current statin use statin allergic patients acute coronary syndromes lesions not appropriate for PCI refusal for participation statin quitting during follow up</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>